Log in

NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, Forecast & News

-0.11 (-3.83 %)
(As of 12/12/2019 03:35 AM ET)
Today's Range
Now: $2.76
50-Day Range
MA: $2.30
52-Week Range
Now: $2.76
Volume2.58 million shs
Average Volume1.76 million shs
Market Capitalization$409.50 million
P/E RatioN/A
Dividend YieldN/A
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCRX



Sales & Book Value

Annual Sales$20.65 million
Book Value$0.45 per share


Net Income$-101,250,000.00
Net Margins-1,129.38%


Market Cap$409.50 million
Next Earnings Date3/2/2020 (Estimated)

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.03. The biotechnology company earned $1.78 million during the quarter, compared to the consensus estimate of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. View BioCryst Pharmaceuticals' Earnings History.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for BioCryst Pharmaceuticals.

What price target have analysts set for BCRX?

8 equities research analysts have issued 1-year price targets for BioCryst Pharmaceuticals' shares. Their forecasts range from $4.00 to $15.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $8.93 in the next year. This suggests a possible upside of 223.5% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to achievement of price target. We reiterate our Buy rating and our price target of $13 is based on the following risk-adjusted sum-of-the-parts NPV-DCF: $11.1 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.2 for peramivir + $0.4 in cash. We assume a discount rate of 13.5%." (5/22/2019)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

Media coverage about BCRX stock has been trending negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for BioCryst Pharmaceuticals.

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 15,750,000 shares, an increase of 13.0% from the September 30th total of 13,940,000 shares. Based on an average daily trading volume, of 1,440,000 shares, the short-interest ratio is presently 10.9 days. Currently, 14.5% of the company's stock are sold short. View BioCryst Pharmaceuticals' Current Options Chain.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include El Pollo LoCo (LOCO), Idera Pharmaceuticals (IDRA), Inovio Pharmaceuticals (INO), Virtu Financial (VIRT), Advanced Micro Devices (AMD), La Jolla Pharmaceutical (LJPC), Alcoa (AA), Exelixis (EXEL), Sangamo Therapeutics (SGMO) and Macrocure (MCUR).

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (3.28%), Point72 Asset Management L.P. (2.20%), First Midwest Bank Trust Division (0.37%), Squarepoint Ops LLC (0.24%), Rhumbline Advisers (0.16%) and Russell Investments Group Ltd. (0.15%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Which institutional investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Voloridge Investment Management LLC and First Midwest Bank Trust Division. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Which institutional investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Squarepoint Ops LLC, Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Redmile Group LLC, California Public Employees Retirement System, Virtu Financial LLC and Rhumbline Advisers. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski and Steve Aselage. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $2.76.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $409.50 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.View Additional Information About BioCryst Pharmaceuticals.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is http://www.biocryst.com/.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]

MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Reverse Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel